The following represents a list of scientific presentations from the past 3 years. These publications are provided for individual, educational purposes for US healthcare professionals only and are not a substitute for consultation and review of reference materials and complete medical literature pertaining to an investigational compound or individual product. Please note that individual publications are only current as of the date listed and may be updated by additional data and/or publications. Please do not copy or distribute further. Further reproduction or distribution is strictly prohibited without permission from the copyright owner(s). Content may be subject to congress and publisher copyright permissions.
The scientific information may include data on investigational use(s) of compounds for which efficacy and safety have not been established.
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Disease Worsening and Progression in Patients with Indolent Systemic Mastocytosis: A US Population-Level Analysis Using Health Claims-Based Dataset
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Symptomatology and Diagnostic Journey of Patients Diagnosed with Systemic Mastocytosis in The US Oncology Network
American Academy of Allergy, Asthma & Immunology (AAAAI) | Oral presentation February 24, 2023
Avapritinib
Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis (ISM) In the Registrational, Double-Blind, Placebo-Controlled PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Oral presentation February 24, 2023
Avapritinib
Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double-Blind Placebo-Controlled PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Avapritinib
Avapritinib Improved Symptoms and Quality of Life in Patients with Indolent Systemic Mastocytosis in the PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
PROSPECTOR: A Global, Prospective Study to Determine the Prevalence of the KIT D816V Mutation in Peripheral Blood From Patients With Evidence of Systemic Mast Cell Activation
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Real-world chart pull data on the clinical presentation and diagnosis of indolent systemic mastocytosis
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Development of Scalable, Electronic Health Record (EHR)-Based Screening for Undiagnosed Systemic Mastocytosis: PREDICT-SM
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Development of a Clinical Scoring System to Identify Conditions of Mast Cell Proliferation in a Community Setting
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
Avapritinib
An Updated Analysis on Safety and Efficacy of Avapritinib in Patients With Advanced Systemic Mastocytosis From the EXPLORER Clinical Study: Long-term Efficacy and Safety
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
BLU-263
AZURE: A Phase 1/2 Study of BLU-263 as Monotherapy and in Combination with Azacitidine in Patients With Advanced Systemic Mastocytosis
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
NGS Testing Practices and Molecular Profile Landscape of the KIT Gene in Systemic Mastocytosis: Real-world Insights From Selected European Countries
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
Disease Progression in Patients with Systemic Mastocytosis: A US Population-Level Analysis Using Health Claims-Based Dataset
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 10, 2022
Avapritinib
Avapritinib as first-line therapy in patients with advanced systemic mastocytosis: Efficacy and safety from the PATHFINDER clinical study
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
Pralsetinib
Pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer: updated data from the ARROW trial
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
Pralsetinib
AcceleRET Lung: a phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
BLU-451
A phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
BLU-701
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
BLU-945
A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non-small cell lung cancer (NSCLC) (SYMPHONY trial-in-progress)
American Society of Clinical Oncology (ASCO) Annual Meeting | Oral presentation June 4, 2022
Avapritinib
Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST)
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-945 & BLU-701
Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-945
Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA in the phase 1/2 SYMPHONY study
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-222
BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-451
LNG-451 (BLU-451), a potent inhibitor of EGFR exon 20 insertion mutations with high CNS exposure
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
Avapritinib, BLU-5675, & BLU-7444
Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of Imatinib-resistant GIST
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-451
LNG-451 (BLU-451) is a Potent, CNS-Penetrant, Wild-Type EGFR Sparing Inhibitor of EGFR Exon 20 Insertion Mutations
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
Utility of a Validated Disease-Specific Measure to Assess Symptomology in Patients with Indolent Systemic Mastocytosis (ISM)
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
Comorbidity and Disability in Medicare Beneficiaries Newly Diagnosed with Non-Advanced Systemic Mastocytosis (Non-AdvSM)
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
Disease Symptomology, Quality of Life (QoL), and Employment Status Among Patients with Systemic Mastocytosis (SM)
British Thoracic Oncology Group (BTOG) Annual Conference | Poster January 28, 2022
BLU-945 & BLU-701
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer driven by EGFR mutations
American Society of Hematology (ASH) Annual Meeting | Poster December 12, 2021
Avapritinib
Efficacy of Avapritinib in Patients With Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses From the Phase 2 Open-Label, Single-Arm, PATHFINDER Study
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 11, 2021
Avapritinib
Effective Control of Advanced Systemic Mastocytosis with Avapritinib: Mutational Analysis from the EXPLORER Clinical Study
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 9, 2021
Avapritinib
Healthcare Resource Utilization and Costs of Advanced Systemic Mastocytosis Among Medicare Fee for Service Beneficiaries
American Society of Hematology (ASH) Annual Meeting | Poster December 9, 2021
Avapritinib
Healthcare Resource Utilization and Costs of Medicare Fee for Service Beneficiaries Newly Diagnosed with Moderate to Severe Non-Advanced Systemic Mastocytosis
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe | Poster November 30, 2021
Avapritinib
Matching-Adjusted Indirect Comparisons of Avapritinib Versus Midostaurin for the Treatment of Patients with Advanced Systemic Mastocytosis
2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day | Poster November 19, 2021
Avapritinib
A phase 1/2 study of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling
American Association for Cancer Research (AACR) Annual Meeting | Oral presentation October 7, 2021
BLU-945
A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
The World Conference on Lung Cancer (WCLC) | Oral presentation September 8, 2021
Pralsetinib
Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer
European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Annual Congress 2021 | Oral presentation July 11, 2021
Avapritinib
Avapritinib improves overall symptoms, skin lesions and quality of life in patients with advanced systemic mastocytosis in the PATHFINDER study
European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer | Oral presentation June 30, 2021
Avapritinib
Safety and Efficacy Results from an Open-label, Multicentre, Phase I/II Study of Avapritinib in Chinese Patients with Gastrointestinal Stromal Tumor (GIST): A Bridging Study of NAVIGATOR
European Hematology Association (EHA) Virtual Congress | Oral presentation June 11, 2021
Avapritinib
Efficacy and safety of avapritinib in patients with advanced systemic mastocytosis: Interim results from the open-label, single-arm, phase 2 PATHFINDER study
2021 Society for Neuro-Oncology (SNO) Pediatric Conference | Poster June 10, 2021
Avapritinib
A phase 1/2, single-arm study to evaluate the safety, pharmacokinetics, and antitumor activity of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 4, 2021
Pralsetinib
Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: update from the ARROW trial
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 4, 2021
Pralsetinib
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: update from the ARROW trial
Academy of Managed Care Pharmacy (AMCP) Annual Meeting | Poster April 12, 2021
Pralsetinib
Budget Impact of Pralsetinib for Treatment of Metastatic RET Fusion Positive Non-Small Cell Lung Cancer
Academy of Managed Care Pharmacy (AMCP) Annual Meeting | Poster April 12, 2021
Avapritinib
Economic Burden of Advanced Systemic Mastocytosis: A Real-World Evaluation of Direct Healthcare Resource Utilization and Costs from a United States Payer Perspective
Academy of Managed Care Pharmacy (AMCP) Annual Meeting | Poster April 12, 2021
Avapritinib
Healthcare Burden of Patients Newly Diagnosed with Moderate to Severe Non-advanced Systemic Mastocytosis Using a Real-world Database of US Health Plan Members
American Association for Cancer Research (AACR) Annual Meeting | Oral presentation April 11, 2021
Avapritinib
PATHFINDER: Interim analysis of avapritinib in patients with Advanced Systemic Mastocytosis (AdvSM)
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-222
Development of a selective CDK2-E inhibitor in CCNE-aberrant cancers
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-852
MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-945
BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-701
BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-263
Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
Avapritinib
Changes in mast cell numbers and phenotype in patients with indolent systemic mastocytosis treated with avapritinib
The World Conference on Lung Cancer (WCLC) | Oral presentation January 28, 2021
Pralsetinib
AcceleRET Lung: a phase 3 study of first-line pralsetinib in patients with RET-fusion+ advanced/metastatic NSCLC
The World Conference on Lung Cancer (WCLC) | Oral presentation January 28, 2021
Pralsetinib
Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion + Non-Small Cell Lung Cancer after Platinum-based Chemotherapy
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 7, 2020
Avapritinib
PIONEER Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 7, 2020
Avapritinib
Perceptions of Patient Disease Burden and Management Approaches of Systemic Mastocytosis (SM) By Healthcare Providers (HCPs): Results from the TouchStone SM Survey
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 7, 2020
Avapritinib
Increased Detection of KIT D816V Mutation in Peripheral Blood Samples from Patients with Indolent Systemic Mastocytosis (ISM) in the Phase 2 PIONEER Study Using a High Sensitivity Droplet Digital (dd) PCR Assay Compared with Next Generation Sequencing (NGS)
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 6, 2020
Avapritinib
Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 5, 2020
Avapritinib
Patient Reported Outcomes Among Systemic Mastocytosis (SM) Patients in Routine Clinical Practice: Results from the TouchStone Survey
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 5, 2020
Avapritinib
Results from PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent Systemic Mastocytosis
Academy of Managed Care Pharmacy (AMCP) Annual Meeting | Poster October 20, 2020
Avapritinib
The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with
Gastrointestinal Stromal Tumors
The World Conference on Lung Cancer (WCLC) | Oral presentation October 17, 2020
Pralsetinib
Analysis of Resistance Mechanisms to Pralsetinib (BLU-667) in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
European Society for Medical Oncology (ESMO) Virtual Congress | Oral presentation September 20, 2020
Pralsetinib
Results from the registrational phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients with advanced RET mutation-positive medullary thyroid cancer
European Society for Medical Oncology (ESMO) Virtual Congress | Oral presentation September 18, 2020
Avapritinib
Long-term efficacy, tolerability and overall survival in patients with unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumor treated with avapritinib: NAVIGATOR phase 1 trial update
European Society for Medical Oncology (ESMO) Virtual Congress | Poster September 17, 2020
Avapritinib
Clinical Efficacy Comparison of Avapritinib With Other Tyrosine Kinase Inhibitors (TKIs) in Gastrointestinal Stromal Tumors (GIST) With PDGFRA D842V Mutation: A Retrospective Analysis of Clinical Trial and Real-World Data
European Society for Medical Oncology (ESMO) Virtual Congress | Poster September 17, 2020
BLU-945
BLU-945, a highly potent and selective 4th-generation EGFR TKI for the treatment of EGFR+/T790M/C797S resistant NSCLC
Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress | Poster June 12, 2020
Avapritinib
Results from PIONEER: a randomized, double-blind, placebo-controlled, Phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM)
Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress | Poster June 12, 2020
Avapritinib
Avapritinib induces responses in patients with advanced systemic mastocytosis (AdvSM), regardless of prior midostaurin therapy
European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress | Oral presentation June 6, 2020
Avapritinib
Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study
American Society of Clinical Oncology (ASCO) Virtual Scientific Program | Oral presentation May 31, 2020
Pralsetinib
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors
American Society of Clinical Oncology (ASCO) Virtual Scientific Program | Oral presentation May 29, 2020
Pralsetinib
AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET Fusion+ Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC)
American Society of Clinical Oncology (ASCO) Virtual Scientific Program | Poster May 29, 2020
Pralsetinib
Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer (NSCLC)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe | Poster May 18, 2020
Avapritinib
Budget Impact Analysis of AYVAKIT™ (avapritinib) in Patients with Gastrointestinal Stromal Tumors and a PDGFRA Exon 18 Mutation
American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Oral Abstracts, Case Reports and Poster Sessions | Oral presentation March 16, 2020
Avapritinib
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
American Society of Hematology (ASH) Annual Meeting | Poster December 8, 2019
Avapritinib
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Connective Tissue Oncology Society (CTOS) Annual Meeting | Oral presentation November 14, 2019
Avapritinib
Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose
Connective Tissue Oncology Society (CTOS) Annual Meeting | Oral presentation November 14, 2019
Avapritinib
Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥4th Line and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe | Poster November 7, 2019
Avapritinib
Psychometric Performance of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe | Poster November 7, 2019
Avapritinib
Psychometric Evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) in patients with Advanced Systemic Mastocytosis
European Society for Medical Oncology (ESMO) Annual Meeting | Poster September 30, 2019
Pralsetinib
Treatment With Pralsetinib (BLU-667), a Potent and Selective RET Inhibitor, Provides Rapid Clearance of ctDNA in Patients With RET-Altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
European Society for Medical Oncology (ESMO) Annual Meeting | Poster September 22, 2019
Avapritinib
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (GIST)
The World Conference on Lung (WCLC) | Poster September 9, 2019
Pralsetinib
Pralsetinib (BLU-667) Demonstrates Robust Activity In RET-Fusion-Driven Intracranial Tumor Models
European Hematology Association (EHA) Annual Meeting | Oral presentation June 15, 2019
Avapritinib
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) With Advanced Systemic Mastocytosis (AdvSM)
American Society of Clinical Oncology (ASCO) Annual Meeting | Oral presentation June 3, 2019
Pralsetinib
Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients With Advanced RET-Fusion+ Non-small Cell Lung Cancer
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 1, 2019
Avapritinib
Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
American Society of Clinical Oncology (ASCO) Annual Meeting | Oral presentation May 31, 2019
Pralsetinib
Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients With Advanced RET-altered Thyroid Cancers
American Association for Cancer Research (AACR) Annual Meeting | Oral presentation March 30, 2019
Pralsetinib
Discovery of BLU-667 for RET-driven cancers
Use the filters to view congress data presentations.
The following represents a list of manuscripts published over the past 3 years. These publications are provided for individual, educational purposes for US healthcare professionals only and are not a substitute for consultation and review of reference materials and complete medical literature pertaining to an investigational compound or individual product. Please note that individual publications are only current as of the date listed and may be updated by additional data and/or publications. Please do not copy or distribute further. Further reproduction or distribution is strictly prohibited without permission from the copyright owner(s).
The scientific information may include data on investigational use(s) of compounds for which efficacy and safety have not been established.
NEJM Evidence May 23, 2023
Avapritinib
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Future Medicine February 4, 2022
Avapritinib
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis
Nature Medicine December 6, 2021
Avapritinib
Safety and Efficacy of Avapritinib in Advanced Systemic Mastocytosis: the Phase 1 EXPLORER trial
Nature Medicine December 6, 2021
Avapritinib
Efficacy and Safety of Avapritinib in Advanced Systemic Mastocytosis: Interim Analysis of the Phase 2 PATHFINDER trial
Orphanet October 18, 2021
Psychometric Evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a Phase 2 Clinical Study
Orphanet October 8, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Journal of Clinical Oncology October 1, 2021
Avapritinib
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Expert Review of Hematology August 6, 2021
Avapritinib
Avapritinib for Systemic Mastocytosis
The Lancet Diabetes and Endocrinology June 9, 2021
Pralsetinib
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
The Lancet Oncology June 9, 2021
Pralsetinib
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Oncologist April 1, 2021
Avapritinib
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least 3 Prior Lines of Therapy
The Oncologist April 1, 2021
Avapritinib
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
BMC Cancer March 1, 2021
Avapritinib
Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data
European Journal of Cancer January 16, 2021
Avapritinib
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
The Lancet Oncology June 29, 2020
Avapritinib
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Cancer Discovery October 1, 2019
Fisogatinib
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Cancer Discovery October 1, 2019
Fisogatinib
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
Use the filters to view congress data presentations.
